cyrilzakka/clinical-trials huggingface dataset:
10 600 nm Ablative Fractional Laser Treatment of Scars: a Prospective Single Blinded Within Patient Controlled Randomized Trial

Rationale The cosmetic aspect of scars is a frequent reason for consultation. It plays an important role in patient satisfaction and self-image. Several treatment modalities are proposed for scars with variable success.

Ablative fractional laser treatment is a rather new concept. Many microscopic small laser beams target the dermis in a grid pattern. The vertical columns of skin hit by the laser beams heat up. This thermal effect stimulates the wound healing and potentially leads to a remodeling of the skin structure.

Ablative fractional laser treatment has been used successfully for treatment of pigment changes, wrinkles, acne scars and thermal burn wounds. It has been reported that CO2 ablative fractional laser treatment has a positive clinical effect on various types of scars however this has not been proven yet in a prospective randomized trial. The low morbidity of the treatment and the lack of convincing adapted treatment modalities for various types of scars make this treatment attractive.

That's why the investigators aim with this randomized study to evaluate the clinical effect and the safety of 10 600 nm ablative fractional laser therapy for patients with recent scars due to surgical interventions.

Goal Evaluate the efficacy of three 10 600 nm ablative fractional laser treatments for the above mentioned scars, three months after the last laser treatment, with a prospective randomized intra-patient controlled study.

Study design Prospective single blinded randomized intra-patient controlled study. The study comprises 4 study visits.

Study population The population consists of one group of patients with scars after recent surgical operations. The patients must meet the inclusion and exclusion criteria described in the protocol.

Method The scar will be divided in two equal halves. The two halves will be randomized. One part will not be treated. The other part will undergo three times the 10 600 nm ablative laser therapy with 4 weeks interval between the treatments. The efficacy of the treatment will be evaluated three months after the last treatment with objective and subjective parameters.

Most important study endpoints:

* Evaluation of the efficacy of the treatment. A blinded clinical scar evaluation will be done of the treated and untreated parts with the POSAS scar scale, by a study collaborator and by the patient himself, on a category scale of 0 to 10 (0 = normal skin, 10 = worst scar imaginable), before start and twelve weeks after the last treatment.
* Evaluation of the pain related to the treatment. The pain will be scored by the patient with the VAS category scale from 0 to 10 (0 = no pain, 10 = worst pain ever).
* Evaluation of the side effects of the treatment. A standardized form will be used.
* Evaluation of the global patient satisfaction regarding the treatment.
* Clinical photos, before start and twelve weeks after the last treatment.


Eligibility Criteria:
Inclusion Criteria:

* Scars caused by surgical intervention, that are 2 months old
Efficacy of Calcifediol Supplementation in Asthma Control in Asthmatic Patients With Vitamin D Deficiency (ACViD)

Introduction: There are many cross-sectional studies in children and adults indicating that low vitamin D levels in asthmatic patients are correlated with poorer asthma control, poorer lung function, decreased response to glucocorticoids and more frequent exacerbations. Moreover, as there is a significant group of asthmatic patients having insufficient control of their disease, despite high doses of inhaled corticosteroids, we have investigated new treatment alternatives, which include vitamin

Objective: To determine the efficacy of vitamin D supplementation in asthmatic patients with vitamin D deficiency in degree of asthma control.

Materials and methods: A prospective, controlled, randomised, triple-blind study was conducted with a follow-up of 6 months. The patients recruited were over 18 years of age with a medical diagnosis of bronchial asthma and serum 25(OH)D3 levels \< 30 ng/ml. Patients were excluded if they had a smoking habit ≥ 10 pack-years, taking vitamin D supplements, kidney disease (creat. \> 2 mg/dl), hypercalcaemia (corrected with proteins \> 10.5 mg/dl), a repeat episodes of renal colic, any gastrointestinal disease that might interfere with vitamin D absorption, or severe psychosocial problems, or were pregnant or breast-feeding. The randomisation process assigned patients to one of two groups: a group that received vitamin D (in the form of calcifediol (Hidroferol®) in 16,000-IU ampoules taken weekly by the oral route) and another group that received placebo in a presentation with an identical appearance and the same administration regimen. Demographic, clinical, spirometry and laboratory endpoints were collected. The primary endpoint was degree of asthma control as determined by the internationally validated Asthma Control Test (ACT). The secondary endpoints were asthma exacerbations, dose of inhaled corticosteroids and quality of life as measured using the Mini-AQLQ (Asthma Quality of Life Questionnaire).


Eligibility Criteria:
Inclusion Criteria:

* Medical diagnosis of bronchial asthma
* serum 25(OH)D3 levels \< 30 ng/ml.

Exclusion Criteria:

* smoking habit ≥ 10 pack-years,
* taking vitamin D supplements,
* kidney disease (creat. \> 2 mg/dl),
* hypercalcaemia (corrected with proteins \> 10.5 mg/dl),
* repeat episodes of renal colic,
* any gastrointestinal disease that might interfere with vitamin D absorption,
* severe psychosocial problems,
* pregnant
* breast-feeding
A Long Term Extension Study of E2080 in Lennox-Gastaut Patients

To investigate the safety of long term administration of E2080 in the patients with Lennox-Gastaut syndrome who completed the E2080-J081-304 Study.


Eligibility Criteria:
Inclusion criteria:

1. Participants who have completed the evaluation of Week 12 of the E2080-J081-304 study.
2. Male participants with reproductive ability and female participants with child-bearing potential, or their partners, had to be able to take medically appropriate contraceptive measures.
3. Participants who have provided a written informed consent to participate in this clinical trial until the evaluation of week 12 of the E2080-J081-304 study.
4. Participants who had a family member or a caregiver capable of recording the reporting diary, providing participant information necessary for the study, assisting treatment compliance, and accompanying the participant on scheduled visit days during the study period.

Exclusion criteria:

1. Participants who were judged by the investigator that they are unfit to participate in this clinical study for safety reasons based on the information up to the evaluation of week 12 of the E2080-J081-304 Study.
2. Participants who were judged by the investigator that they are likely to become non-compliant with administration during the clinical trial period.
3. Participants who were judged by the investigator that they were unfit to participate in this clinical trial.
Effects of Kinesiotherapy Exercises With Cervical Mobilization in Cervicobrachial Neuralgia

To evaluate the effects of kinesiotherapy exercises with cervical mobilization in Cervicobrachial Neuralgia.

Cervicobrachial Neuralgia is characterized by pain and discomfort in the arm, specifically in conjunction with pain in the cervical spine. It has been observed that a significant number of patients seeking therapy for cervical spine diseases are affected by this type of pain. When an illness is chronic, it has a tendency to manifest as a persistent or recurring issue that has a negative impact on an individual's mental and physical well-being.

It is a randomized clinical trial. 30 patients fulfilling the inclusion and exclusion criteria will be recruited by non-probability convenience sampling and then randomly divided in two groups using lottery method. Group A will receive the strengthening and kinesiotherapy exercises along with Brugger's relief position training with 10 minutes per session and cervical lateral glide mobilization, 3 times a week. And the group B will receive the cervical lateral glide mobilization. Pain levels will be measured using a visual analogue scale and goniometer will be used to measure neck ranges.The data will be analyzed by using SPSS version25.

Eligibility Criteria:
Inclusion Criteria:

* Both male and female
* Age: 30-50 years
* Positive upper limb neurodynamic test
* Patients having neck pain radiating to upper limb and limited ROM with articular dysfunction.

Exclusion Criteria:

* Patients diagnosed with fibromyalgia
* Surgery of cervical/thoracic spine
* Limited glenohumeral joint movement
* Presence of neurological disease (stroke, multiple sclerosis)
Studies in Porphyria IV: Gonadotropin-Releasing Hormone (GnRH) Analogues for Prevention of Cyclic Attacks

OBJECTIVES:

Assess whether chronic administration of gonadotropin-releasing hormone analogues is safe and effective for the prevention of cyclic attacks of acute porphyria in women.

PROTOCOL OUTLINE: All patients receive a gonadotropin-releasing hormone (GnRH) analogue. Treatment begins on days 1 to 3 of a menstrual cycle.

Low-dose estrogen begins at approximately 3 months. All patients must have a daily calcium intake of at least 1 gram; supplements are allowed.

Patients are followed for at least 1 year.

Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Acute porphyria, i.e.: Acute intermittent porphyria Hereditary coproporphyria Variegate porphyria Definite cyclic attacks with severe abdominal pain and other porphyria symptoms during luteal phase of menstrual cycle only Attacks resolve completely within 5 days of onset of menses, i.e., no symptoms between attacks At least 4 to 6 attacks during the 6 months prior to entry More than half of these attacks must meet the following criteria: Readily distinguishable from menstrual cramps and premenstrual syndrome Required hospitalization for narcotic analgesics, phenothiazines, hematin, intravenous fluids, or other treatment Luteal attacks not requiring hospitalization must be similar in symptoms and differ only in severity No life-threatening porphyria attacks No cyclic abdominal pain unless caused by porphyria --Prior/Concurrent Therapy-- At least 6 months since ovulation suppression --Patient Characteristics-- Reproductive: Menstrual cycle 25-35 days for at least 6 months prior to entry Pelvic exam normal within 60 days prior to entry Pap smear normal, i.e., no dysplasia No amenorrhea No other menstrual abnormality No other gynecologic abnormality Negative pregnancy test Medically approved contraception required for 2 months prior to entry and throughout study OR at least 1 menstrual cycle following tubal ligation Other: No allergy to gonadotropin-releasing hormone analogues No clinically significant abnormal laboratory test results No medical contraindication to protocol treatment
Predicting Outcomes for Covid-19 Using Sonography

This study seeks to investigate the role of lung ultrasound in caring for Covid-19 positive patients and whether it can be used to predict patient deterioration. This information will be vital for healthcare workers who seek to identify Covid-19 pneumonia or patients at risk for deterioration early in the disease course.

As Covid-19 continues to stress hospital-based resources (including personal protective equipment, ancillary staff availability, and imaging study utilization), it is important to assess whether alternative methods for evaluating patients can be utilized to appropriately triage and care for Covid-positive patients. Current limitations of caring for patients with Covid-19 include the exposure of ancillary healthcare workers (including radiological technicians) and the time/resources required to decontaminate traditional radiological equipment such as x-ray or computerized tomography (CT) machines.

Point-of-care ultrasound (POCUS) has the potential to transform healthcare delivery due to its diagnostic and therapeutic expediency. It can be quickly performed at the bedside by experienced clinicians. It it has been shown to reliably and accurately diagnose patients with a variety of lung diseases, including pneumonia. This study seeks to investigate the role of lung ultrasound in caring for Covid-19 positive patients and whether it can be used to predict patient deterioration. This information will be vital for healthcare workers who seek to identify the virus or patients at risk for deterioration early in the disease course. Moreover, it has the potential to reduce the need for x-rays or CTs for Covid-19 patients, which has the potential to alleviate a significant burden currently being placed on the healthcare system.

Eligibility Criteria:
Inclusion Criteria:

* Any adult (18 or more years of age) presenting to the emergency department with symptoms suspicious for Covid-19
* This individual underwent evaluation for Covid-19 via a nasopharyngeal RT-PCR
* This individual received a lung ultrasound by the study authors within 28 days from initial evaluation

Exclusion Criteria:

* Any individual who did not receive a lung ultrasound within 28 days from initial evaluation for covid-19 related illness
An Evaluation of the Effect of the Erchonia FX-405 Laser as an Adjunctive Treatment of Periodontitis

The purpose of this clinical study is to determine the effectiveness of the Erchonia® FX-405 (manufactured by Erchonia Corporation (the Company) in providing a noninvasive adjunctive treatment in combination with periodontal scaling and root planing for improving the treatment of periodontal disease.

The purpose of this clinical study is to determine the effectiveness of the Erchonia® FX-405 (manufactured by Erchonia Corporation (the Company) in providing a noninvasive adjunctive treatment in combination with periodontal scaling and root planing for improving the treatment of periodontal disease. This clinical study is a double-blind design, such that neither the subject, nor the investigators - the investigator administering the treatment with the Erchonia® FX-405™ device (administration investigator) or the investigator recording the outcome measures (assessment investigator) - will be aware of whether the subject has been assigned to the active treatment test group or to the sham treatment control group until after the study is complete. All study subjects, regardless of treatment group assignment will receive active scaling and root planing standard of care therapy in addition to the active or sham therapy with the Erchonia® FX-405™ device.

Eligibility Criteria:
Inclusion Criteria:

* Subject has voluntarily signed a written informed consent form.
* Male or female 22 to 75 years of age, inclusive.
* Subject has no evidence of Localized Aggressive Periodontitis.
* Tooth loss due to periodontitis of ≤ 4 teeth.
* Two or more teeth with the following characteristics: Non 3rd molar, Periodontitis: Stage III (Severity) according to the Interdental CAL (at site of greatest loss) and RBL, as classified by the American Academy of Periodontology (AAP), No evidence of caries, No abscess infection, No previous periodontal surgery within the prior 12 months
* Subject agrees to adhere to study provided home care instructions to maintain adequate oral hygiene during the study duration.
* Subject agrees to refrain from the use of smokeless chewing tobacco for the study duration.
* Subject agrees to refrain from exceeding 40 milligrams per day of inhaled nicotine, encompassing cigarettes, electronic cigarettes, and cigars.
* Subject agrees to refrain from engaging in any other treatments for his or her periodontitis that is outside the scope of this study during his or her participation in this study

Exclusion Criteria:

* Gingival recession which may be genetic, induced secondary to orthodontic treatment, induced secondary to frenulum attachments, or present as a result of dental malocclusion.
* History of oral cancer or HIV in the last 6 months
* Pregnant or intending to become pregnant in the next 8 months.
* Sensitivity to, or contraindication for, light therapy.
* Currently enrolled in a clinical study of an investigational drug or device.
MK0354 Clinical Efficacy and Tolerability Study (0354-004)

A Research Study to Evaluate the Effectiveness and Tolerability of MK0354 vs Placebo (an inactive look alike pill) in Lipid (fat) Altering in Patients with dyslipidemia (a disorder of lipids in the blood)

This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).


Eligibility Criteria:
Inclusion Criteria:

* Patient is between 18 and 75 years of age
* You have taken a statin or other lipid modifying therapy in the last 6-8 weeks
* You have lipid lab values outside of the range specified in the protocol

Exclusion Criteria:

* Patient is a woman who is pregnant or nursing a child
* Patient is a woman who is taking hormonal birth-control
* You are a woman who is planning to donate eggs during the study
* You plan to give blood during the study or have given within the last 8 weeks
* You are a woman who is having menopausal hot flashes or are taking medications to prevent menopausal hot flashes
* You have a known intolerance to or you are allergic to niacin
* You have any of the following medical conditions:
* Poorly controlled or newly diagnosed diabetes (within the last 3 months)
* Thyroid disease (hypothyroidism or hyperthyroidism)
* A history of stroke, heart attack, coronary bypass surgery, angioplasty, unstable angina or similar heart and artery procedures in the past 3 months
* History of hemorrhagic stroke or other non-traumatic hemorrhage
* Peptic ulcer disease in the last 3 months
* An occurrence of gout within the last year and you are not currently taking allopurinol
* Cancer (except for successfully treated skin cancer)
* HIV positive
* You have a history of drug/alcohol abuse within the last year
* You consume more than 2 drinks of alcohol per day
* You do not have access to a telephone
* You take medications that are not allowed in this study. The study doctor or staff will discuss this with you.
* Patient has participated in a study with an investigational drug within the last 30 days
Evidence-based Approach to Reduce Falls in Adult Patients

The project aims to promote patient safety and quality care by reducing preventable falls and falls with injuries using an evidence-based solution.

The project aims to promote patient safety and quality care by reducing preventable falls and falls with injuries using an evidence-based solution: the Fall Tailoring Interventions for Patient Safety (TIPS) intervention. The three objectives include: (a) developing personalized fall prevention interventions for high-risk patients, (b) engaging patients and families in fall prevention initiatives, and (c) promoting effective communication among teams using a bedside visual tool.

Eligibility Criteria:
Inclusion Criteria:

* Adult (≥18 years) inpatients admitted for various medical-surgical conditions in 3 Medical unit at MRMC. All patients will be included in the project except those diagnosed with psychiatric conditions and cognitive impairments.

Exclusion Criteria:

* Patients with psychiatric conditions and cognitive impairments will be excluded from the project. This assessment is routine.
KAP of Dental Practitioners Regarding CRA

The aim of the study is to evaluate the knowledge, attitude, and practice of a group of dental practitioners from Cairo and Riyadh regarding caries risk assessment and management.

Dental caries is a preventable major public health disease affecting people of all ages and substantially impacting overall health. Caries remain the single most common chronic childhood disease. Dental caries is a dynamic and complex process. Several variables influence the occurrence of dental caries, including oral flora, saliva flow and composition, and lifestyle. Dental caries development can be primary (new carious lesion) or secondary (lesion progression or reactivated carious lesions).

There has been much progress over the past several decades in the prevention of dental caries, shifting from the management of dental caries from a "surgical approach" to a "medical prevention strategy", based on a better understanding of the caries disease process.

Caries Risk Assessment (CRA) is a significant part of successfully applying the minimum intervention dentistry philosophy in managing dental caries. As recommended by AAPD, Dental caries-risk assessment should be a routine component of new and periodic examinations by oral health and medical providers. Therefore, this study aims to assess the knowledge, attitude, and practice of a group of dental practitioners from Cairo and Riyadh regarding caries risk assessment and management.

Benefits to Practitioner:

* Increasing awareness of the importance of CRA practices.
* Implementing a positive attitude regarding CRA and management.
* Improve practices toward CRA

Benefits to Patient:

* Increasing the awareness and knowledge of early caries prevention by dentists.
* Increasing awareness about Caries Risk Assessment and management.

Benefits to Community:

• Increasing the knowledge and awareness of the community regarding preventive dentistry and the importance of primary prevention

Eligibility Criteria:
Inclusion Criteria:

* Licensed Egyptian and Saudi general dentists.

Exclusion Criteria:

* Undergraduate dental students
* Dental specialists
* Dentists who refused to participate